Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA)
| Autor: | Violetta R. Mustafina, Dmitriy A. Sychev, Sardana M. Tarabukina, Denis S Fedorinov, Zoya A. Rudykh, Nyurguiana V. Popova, Jana V. Chertovskikh, K. B. Mirzaev, Nadezda R. Maximova |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty CYP2D6 Adrenergic beta-Antagonists Coronary Disease 030204 cardiovascular system & hematology Polymorphism Single Nucleotide Russia 03 medical and health sciences 0302 clinical medicine Gene Frequency Internal medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Genotyping Metoprolol Aged Dose-Response Relationship Drug business.industry Haplotype Middle Aged Atenolol Pharmacogenomic Testing Cytochrome P-450 CYP2D6 Genetic marker Bisoprolol business Pharmacogenetics medicine.drug |
| Zdroj: | Drug metabolism and personalized therapy. 33(4) |
| ISSN: | 2363-8915 |
| Popis: | BackgroundThe aim of this study was to determine carrier frequencies of the polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease (CHD) patients in Russian and Yakut ethnic groups. The association between the administration of higher doses of bisoprolol and metoprolol and the carriage of these polymorphic markers related to the decreased function of the haplotype of CYP2D6 was also studied.MethodsThe study included 201 CHD patients (aged 66±8.7 years) receiving metoprolol in titrated dose (12.5–150 mg), bisoprolol (2.5–10 mg) or atenolol (50 mg). Ninety-three patients were Russian (30 men and 63 women), and 108 patients were Yakut (54 men and 54 women).ResultsIn genotyping CHD patients in the Russian and Yakut ethnic groups, there was no significant difference in the prevalence rate of the polymorphic markers G1846A (10.8 vs. 10.2; p=0.871) and C100T (16.1 vs. 16.2; p=1). In patients carrying the polymorphic marker G1846A, the dose of bisoprolol was established to be lower than that in the control group (p=0.0289).ConclusionsThe carriage frequency of polymorphic markers, which theoretically should differ between Russians and Yakuts as representatives of two different races, in practice turned out to be the same. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|